Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
SNDX
#1700
Syndax Pharmaceuticals, Inc.
21.7
1
+6.89%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+6.89%
Changement Mensuel
+1.92%
Evolution sur 6 mois
+32.54%
Changement Annuel
+43.02%
Clôture Précédente
20.3
1
Open
21.7
1
Bid
Ask
Low
21.7
1
High
21.7
1
Volume
124
Marchés
Actions des Marchés US
Soins de Santé
SNDX
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
48.24 M
55.01 M
68.44 K
84.97 M
86.02 M
88.2 M
—
Valuation ratios
Enterprise value
957.52 M
982.25 M
-72.6 M
1.56 B
983.16 M
1.72 B
4.54 B
Price to earnings ratio
—
47.59
-10.41
-7.34
-3.55
-6.39
-16.26
Price to sales ratio
—
8.4
—
—
47.8
—
—
Price to cash flow ratio
—
40.29
-11.64
-9.58
-4.12
5.64
-4.96
Price to book ratio
—
2.87
3.33
2.78
3.93
28.16
31.45
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.24
0.06
0.3
0.34
0.44
0.54
0.49
Return on equity %
0.29
0.06
0.32
0.38
1.11
4.42
2.43
Return on invested capital %
2 493.6
929.46
4 423.93
2 612.85
1 177.24
746.06
792.31
Gross margin %
100
100
—
—
100
97.87
400
Operating margin %
4 708.17
18.77
—
—
1 434.43
158.45
817.14
EBITDA margin %
—
—
—
—
—
-163.2
—
Net margin %
4 822.54
17.84
—
—
1 346.11
165.6
844.3
Liquidity ratios
Quick ratio
—
—
—
—
5.82
4.12
18.85
Current ratio
15.84
21.68
16.85
10
5.82
4.4
19.55
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.01
0.37
0
0
0.04
0.27
0.3
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0.06
0.04
0
—
0.46
-0.01
-0.04
Long term debt to total equity ratio
0.07
0.05
0
—
1.15
-0.09
-0.21
Per share metrics
Operating cash flow per share
—
0.54
2.2
2.28
3.21
3.73
3.74
EBIT per share
—
—
—
—
—
-3.19
—
EBITDA per share
—
—
—
—
—
-3.25
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
8.2
7.83
8.11
6.69
4.55
20.8
Net current asset value per share
—
8.36
8.06
8.25
7.04
6.1
24.74
Tangible book value per share
—
7.62
7.69
7.88
3.37
0.75
6.4
Working capital per share
—
7.98
7.58
7.43
5.83
4.71
19.63
Book value per share
—
7.62
7.69
7.88
3.37
0.75
6.4
Nouvelles
Stifel relève l’objectif de cours de Syndax Pharmaceuticals sur les ventes de médicaments
Stifel raises Syndax Pharmaceuticals stock price target on drug sales
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript
Syndax T4 2025 : chiffre d’affaires en hausse de 50%, trajectoire de rentabilité détaillée
Syndax Q4 2025 slides: revenue surges 50%, profitability path outlined
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates
Le BPA de Syndax Pharmaceuticals a manqué les attentes de 0,19$, le CA a surpassé les prévisions
Syndax Pharmaceuticals earnings missed by $0.19, revenue topped estimates
Syndax face à un test crucial alors que le lancement de ses médicaments anticancéreux s’accélère
Syndax faces earnings test as cancer drug launches accelerate
Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 (NASDAQ:SNDX)
Le PDG de Syndax Pharmaceuticals vend des actions SNDX pour 152.835€